Loading
The study of about 8,000 people that Harbinger Health used to build and validate its blood test for many cancers.
CORE-HH (NCT05435066) is an observational study sponsored by Harbinger Health. It collected blood, tissue and clinical data from people with a variety of cancers and from people without cancer to develop a screening test for early cancer detection.
The registry record, read on 29 October 2026, gives its status as completed, with 8,038 participants enrolled, a start on 21 June 2022 and primary completion on 11 June 2025.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/